Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oritavancin vs Vancomycin in ABSSSI (SOLO II)
NCT01252732Phase 3Completed
- Sponsor
- Melinta Therapeutics
- Start
- Dec 2010
- Primary completion
- Jun 2013
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of oritavancin in acute bacterial skin and skin structure infection (ABSSSI), sponsored by Melinta Therapeutics. Started Dec 2010; status: completed.
02
Drugs
oritavancin
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on NCT01252732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01252732.